| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $1,385,976 ) |
| | 2025 | 2025 | PROVIDENCE HEALTH & SERVICES - OREGON | 1801 LIND AVE SW STE 9016 | RENTON | WA | 98057-3368 | KING | USA | R01CA293806 | Enhancing the efficacy of radiation by spatially restricting anti-TGFb treatment to the tumor | 000 | 1 | NIH | 3/28/2025 | $585,976 |
| | 2025 | 2022 | PROVIDENCE HEALTH & SERVICES - OREGON | 1801 Lind Ave SW, #9016 | Renton | WA | 98057-3368 | KING | USA | CE154731 | Community Project Funding/Congressionally Directed Spending - Construction | 01 | 1 | HRSA | 4/11/2025 | $0 |
| | 2025 | 2022 | PROVIDENCE HEALTH & SERVICES - OREGON | 1801 Lind Ave SW, #9016 | Renton | WA | 98057-3368 | KING | USA | CE154731 | Community Project Funding/Congressionally Directed Spending - Construction | 00 | 1 | HRSA | 3/14/2025 | $800,000 |
|
| Issue Date FY: 2024 ( Subtotal = $517,422 ) |
| | 2024 | 2024 | PROVIDENCE HEALTH & SERVICES - OREGON | 1801 LIND AVE SW STE 9016 | RENTON | WA | 98057-3368 | KING | USA | R21CA277250 | DNASE1L3 regulation of anti-tumor immune responses following radiation therapy | 000 | 2 | NIH | 11/29/2023 | $175,664 |
| | 2024 | 2024 | PROVIDENCE HEALTH & SERVICES - OREGON | 1801 LIND AVE SW STE 9016 | RENTON | WA | 98057-3368 | KING | USA | R21CA277250 | DNASE1L3 regulation of anti-tumor immune responses following radiation therapy | 001 | 2 | NIH | 4/17/2024 | $9,758 |
| | 2024 | 2024 | PROVIDENCE HEALTH & SERVICES - OREGON | 1801 LIND AVE SW STE 9016 | RENTON | WA | 98057-3368 | KING | USA | K22CA248849 | DISSECTING THE ROLES OF FAT1 AND NEAT1 IN SOFT TISSUE SARCOMA DEVELOPMENT AND METASTASIS USING NOVEL IN VIVO SARCOMA MODELS | 000 | 3 | NIH | 7/19/2024 | $162,000 |
| | 2024 | 2024 | PROVIDENCE HEALTH & SERVICES - OREGON | 1801 LIND AVE SW STE 9016 | RENTON | WA | 98057-3368 | KING | USA | R03CA283104 | Develop a PET radiotracer suitable for in vivo imaging of TGFβ | 000 | 1 | NIH | 6/24/2024 | $170,000 |
| | 2024 | 2023 | PROVIDENCE HEALTH & SERVICES - OREGON | 1801 LIND AVE SW STE 9016 | RENTON | WA | 98057-3368 | KING | USA | R03HS029544 | Assessing the impact of financial incentives on provision of interpretive services in Medicaid | 001 | 1 | AHRQ | 7/24/2024 | $0 |
| | 2024 | 2023 | PROVIDENCE HEALTH & SERVICES - OREGON | 1801 LIND AVE SW STE 9016 | RENTON | WA | 98057-3368 | KING | USA | R03HS029544 | Assessing the impact of financial incentives on provision of interpretive services in Medicaid | 000 | 1 | AHRQ | 11/9/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $491,030 ) |
| | 2023 | 2023 | PROVIDENCE HEALTH & SERVICES - OREGON | 4400 NE HALSEY ST BLDG 2 STE 690 | PORTLAND | OR | 97213-1545 | MULTNOMAH | USA | R21CA277250 | DNASE1L3 regulation of anti-tumor immune responses following radiation therapy | 000 | 1 | NIH | 12/16/2022 | $234,218 |
| | 2023 | 2023 | PROVIDENCE HEALTH & SERVICES - OREGON | 1801 LIND AVE SW STE 9016 | RENTON | WA | 98057-3368 | KING | USA | R03HS029544 | Assessing the impact of financial incentives on provision of interpretive services in Medicaid | 000 | 1 | AHRQ | 9/1/2023 | $94,812 |
| | 2023 | 2023 | PROVIDENCE HEALTH & SERVICES - OREGON | 1801 LIND AVE SW STE 9016 | RENTON | WA | 98057-3368 | KING | USA | K22CA248849 | DISSECTING THE ROLES OF FAT1 AND NEAT1 IN SOFT TISSUE SARCOMA DEVELOPMENT AND METASTASIS USING NOVEL IN VIVO SARCOMA MODELS | 000 | 2 | NIH | 8/15/2023 | $162,000 |
|
| Issue Date FY: 2022 ( Subtotal = $162,000 ) |
| | 2022 | 2022 | PROVIDENCE HEALTH & SERVICES - OREGON | 4400 NE HALSEY ST BLDG 2 STE 690 | PORTLAND | OR | 97213-1545 | MULTNOMAH | USA | K22CA248849 | DISSECTING THE ROLES OF FAT1 AND NEAT1 IN SOFT TISSUE SARCOMA DEVELOPMENT AND METASTASIS USING NOVEL IN VIVO SARCOMA MODELS | 000 | 1 | NIH | 9/6/2022 | $162,000 |
|
|
